News

Why Summit Therapeutics Stock Soared 8% Higher Today
A large, well-capitalized peer is apparently interested in a partnership deal with the company. The media outlet in question ...
Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain
Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...
2 Soaring Stocks With More Upside Potential to Buy and Hold
Second, SoFi could grow its revenue even without expanding its membership base, by cross-selling additional products to its ...
The AM Reporter2d
Summit Therapeutics (NASDAQ:SMMT) Earns Buy Rating from HC Wainwright
Summit Therapeutics (NASDAQ:SMMT – Get Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a note issued ...
Zacks Investment Research on MSN3d
Wall Street Analysts Believe Summit Therapeutics (SMMT) Could Rally 63.02%: Here's is How to Trade
Shares of Summit Therapeutics PLC (SMMT) have gained 2.8% over the past four weeks to close the last trading session at $21.2 ...
Forbes India5d
Maky Zangenah: Taking cancer drug maker Summit Therapeutics to staggering heights
Alongside her husband, Bob Duggan, Maky Zanganeh has guided cancer drug developer Summit Therapeutics to reach staggering new ...
MarketWatch5d
Revolution Medicines, Summit Therapeutics Partner to Evaluate Combination of Treatments in Certain Cancers
Revolution Medicines and Summit Therapeutics entered into a clinical collaboration in multiple solid-tumor settings to evaluate their respective treatments in combination with each other. Redwood ...
Lineage Cell Therapeutics unveils promising Phase I/IIa OpRegen results at CTS 2025
OpRegen is a suspension of embryonic stem cell-derived RPE cells restoring visual function in degenerative retinal ...